Becton, Dickinson and Company

Jurisdiction

United States

LEI

ICE2EP6D98PQUILVRZ91

ISIN

US0758871091

(BDX)

Sectors

Scores

InsiderPie Expert Score: 55 / 100
Better than peer group:: 51 / 100
Fair value (Benjamin Graham formula): €238.15 43.1% undervalued
Financial strength (Piotroski F-Value): 8 / 9
Fundamental strength relative to industry (Mohanram G-Value): 3 / 7

Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. Read full profile

Fundamentals

Net revenue: €18.24B
Gross margin: 44.9%
EBIT: €2.16B
EBIT margin: 11.8%
Net income: €1.35B
Net margin: 7.4%

Statement period: July 1, 2024 - June 30, 2025 (published August 7, 2025)

Estimates

Fiscal Year	Net revenue	Net income
2026	€19.50B +6.9%	€3.64B +169.1%
2027	€20.37B +4.5%	€3.92B +7.8%
2028	€20.94B +2.8%	€4.09B +4.4%

Dividends

Last dividend amount: $1.04
Ex date: September 5, 2025
Payment date: September 30, 2025
Dividend payout ratio: 74.1%

Analyst ratings

No analyst ratings available

Insider Transactions

Name	Title	Transaction Date	Shares	Price	Value
Feld Michael	EVP & President, Life Sciences	August 22, 2025	-57	$197.99	-$11.29K
HAYES GREGORY	N/A	August 11, 2025	+5.3K	$191.57	+$1.01M
Fraser Claire	N/A	August 8, 2025	-863	$192.30	-$165.95K
Garrison Michael David	EVP & President, Medical	July 18, 2025	-1.2K	$180.29	-$213.64K

Congress transactions

Name	Transaction date	Value
Lisa McClain	August 13, 2025	$1.00K–$15.00K
Lisa McClain	August 13, 2025	$1.00K–$15.00K
Thomas Kean	June 17, 2025	$1.00K–$15.00K
Robert Bresnahan	June 9, 2025	$1.00K–$15.00K
Robert Bresnahan	April 28, 2025	$1.00K–$15.00K